ESTRO 2023 - Abstract Book

S398

Sunday 14 May 2023

ESTRO 2023

Conclusion In this systematic review we observed a higher prevalence rate for retinopathy (6.0%) compared to optic neuropathy (2.0%) for patients undergoing radiation therapy for brain, head and neck cancer. This review emphas the need for future studies considering retinopathy and optic neuropathy as a primary objective parameter. PD-0490 Dose escalation in oesophageal cancer: comparing pre-accrual SCOPE2/PRODIGE-26 RTTQA programmes J. Helbrow 1 , O. Nicholas 1 , G. Lewis 2 , G. Radhakrishna 3 , T. Crosby 4 , S. Gwynne 1,5 1 South West Wales Cancer Centre, Clinical Oncology, Swansea, United Kingdom; 2 Velindre Cancer Centre, Medical Physics, Cardiff, United Kingdom; 3 The Christie, Clinical Oncology, Manchester, United Kingdom; 4 Velindre Cancer Centre, Clinical Oncology, Cardiff, United Kingdom; 5 Swansea University, Medical School, Swansea, United Kingdom Purpose or Objective Radiotherapy (RT) dose escalation (DE) in oesophageal cancer has been evaluated in SCOPE2 (UK) and PRODIGE-26 (France) trials. PRODIGE-26 reports frequent RTTQA protocol deviations at the pre-accrual stage (1): we describe then compare the SCOPE2 experience. Materials and Methods All recruiting centres without previous NeoSCOPE approval were required to submit contours using supplied 3D DICOM datasets. Those using 4D CT planning were also required to delineate a 4D dataset. Necessary clinical information and a radiotherapy planning guidance document were provided, and a “gold standard” contour agreed by the Trial Management Group.